HIV-1 viremia during the first 28 weeks of pregnancy is not associated with mother-to-child transmission by Senise, J.f. et al.
www.bjid.com.br
BJID 2006; 10 (August) 259
Received on 19 February 2006; revised 11 July 2006.
Address for correspondence: Dr.   Jorge F. Senise, Av. Senador
Casimiro da Rocha, 719 São Paulo, SP, Brazil, CEP 04047-001. tel:
+55-11-55891099; fax: +55-11-5549 0158.
E-mail: j.senise@terra.com.br.
The Brazilian Journal of Infectious Diseases 2006;10(4):259-263.
© 2006 by The Brazilian Journal of Infectious Diseases and Contexto
Publishing. All rights reserved.
HIV-1 Viremia During the First 28 Weeks of Pregnancy is Not Associated
With Mother-to-Child Transmission
J.F. Senise1,2, R. Palacios1,2, Z.N. Tanno1, 1Multidisciplinary Group for Infectious Diseases in Pregnancy, São Paulo
L. Lunardi1,2, G.R. Waghabi1, M.J.R. Vaz1, Hospital, Department of Infectious Diseases and  Department of Obstetrics,
RS. Diaz1 and  A. Castelo1 Federal University of São Paulo/Medical School of São Paulo (UNIFESP),
São Paulo, SP; 2Interdisciplinary Center for Infectious Diseases in
Pregnancy, Department of Infectious Diseases and Department of
Gynecology and Obstetrics, Hospital Ipiranga, São Paulo, SP,Brazil
It is currently recommended that antiretroviral prophylaxis to prevent mother-to-child transmission
(MTCT) of HIV be initiated at 14 weeks of gestation. However, the relevance of early-gestation HIV
viral load level for intrauterine MTCT is unknown. The objective of this study was to determine the
relationship between prenatal maternal viral load and intrauterine MTCT. Records of HIV-infected
pregnant women in two centers in Brazil, from 1999 to 2004 were analyzed. Three pregnancy periods
were considered: earlier than 14 weeks, 14 to 27 6/7 weeks, and 28 weeks of gestation or more.
Peripartum HIV exposure was also computed. Maximum viral load in each period was the measure of
HIV exposure. Four hundred fifty-seven HIV-infected pregnant women were evaluated, but 53 were
excluded. The MTCT rate was 0.49% (2/404−95% confidence interval (CI95) = 0.14−1.79%). Newborns
were not breast-fed. Median viral load for the earlier-than-14-week period was 9,900 copies/mL (P25-
75 1,000−50,775 copies/mL), 8,350 copies/mL (P25-75 707−42,000 copies/mL) for the 14 to 27 6/7-week
period, and 435 copies/mL (P25-75 90−7,775 copies/mL) after the 28-week period. The peripartum
median viral load was 400 copies/mL (P25-75 80−500 copies/mL). MTCT in mothers with VL > 1,000
copies/mL during the first 14 weeks (0.67%, 2/298) was not different from those with VL =1,000 copies/
mL (0.0%, 0/96, P=1). Analogously, in the 14 to 27 6/7-week period, MTCT was similar in groups with
VL higher (0.68%, 2/292) or lower (0%, 0/106) than 1,000 copies/mL (P=1). Regarding VL >1,000 copies/
mL at 28-weeks-or-later and at peripartum periods, MTCT rates were 1.15% (2/173, P = 0.18) and
2.8% (2/71, P = 0.03), respectively. Intrauterine transmission does not seem to be influenced by HIV
viremia during the first 28 weeks of pregnancy.
Key Words: HIV-1, disease transmission, vertical transmission, antiretroviral therapy, highly active,
Brazil, viral load.
According to the United Nations Program on HIV-AIDS/
World Health Organization, approximately five million new
HIV infections occurred worldwide in 2004. Among those
infected, 40% were women of childbearing age, resulting in
approximately 700,000 children being infected [1]. As of June
2004, 310,245 AIDS cases had been reported among Brazilians
over the age of 13. Women accounted for 89,302 cases, 87.6%
of which were sexually transmitted [2]. According to the
Brazilian Ministry of Health, the estimated prevalence of HIV
infection among pregnant women was 0.47% in 2000 [3].
In the absence of effective prophylactic intervention,
approximately 25% of mothers transmitting HIV infection to
their child will do so during pregnancy, and 75% will transmit
the virus during the perinatal period [4]. In the case of
breastfeeding, the risk of transmission can increase 14% to
29% [5,6]. The impact of known risk factors for HIV transmission
during the perinatal period (protracted labor, membrane rupture
for more than four hours and especially perinatal HIV viral load)
is clearly reduced by antiretroviral therapy during pregnancy
and by elective cesarean section (C-section) [7-11]. As a result
of these interventions, perinatal mother-to-child transmission
(MTCT) of HIV has been significantly reduced. Consequently,
intrauterine transmission has become the predominant mode of
MTCT, accounting for up to 80% of all cases [12]. Initiating
antiretroviral therapy at week 28 of gestation [13] can reduce
intrauterine MTCT, which has been correlated with higher
prenatal maternal viral load, suboptimal antiretroviral therapy,
and low birth weight [12]; although data regarding these and
other relevant risk factors for intrauterine MTCT are scarce.
Therefore, effective interventions cannot be devised until the
pathogenic mechanisms of intrauterine transmission are better
understood.
Despite the fact that most guidelines for antiretroviral
therapy in pregnancy recommend it [14,15], the available
evidence does not indicate that prophylactic antiretroviral
therapy initiated by week 14 of gestation affords more
protection than that initiated at week 28 [13,16]. On the other
hand, it has been demonstrated that zidovudine monotherapy
started after 34 weeks of gestation has no impact on
intrauterine MTCT [13,17]. In view of these facts, the objective
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of our study was to analyze the relationship between prenatal
exposure to HIV (particularly during the first 28 weeks of
gestation) and MTCT of HIV.
Material and Methods
All HIV-positive pregnant women receiving prenatal
care between January 1999 and June 2004 at two referral
centers, the Universidade Federal de São Paulo (UNIFESP,
Federal University of Sao Paulo) Hospital São Paulo and
the Hospital Ipiranga, both located in Sao Paulo city, Brazil,
were included in this study. Clinical and laboratory records
were reviewed retrospectively. Medical care, laboratory
tests, and drugs are provided without charge at both
centers. Lactation was routinely inhibited and breastfeeding
discouraged. During the first 72 hours after delivery, and
30 days thereafter, the HIV viral load of the child was
routinely assessed. At one year of age or more, infants
were submitted to HIV ELISA testing. Non-MTCT was
defined as an undetectable HIV viral load in at least two
tests, more than 30 days apart [18].
To assess the influence that HIV exposure during
pregnancy has on MTCT, gestation was divided into three
periods: = 14 weeks; 14-27 weeks; and ≥ 28 weeks. In addition,
the perinatal period was defined as the last four weeks
preceding delivery. The highest recorded viral load in each
period was considered the level of HIV exposure during that
period. In antiretroviral-naïve patients, viral load assessed
before the initiation of treatment was computed in the analysis
as HIV exposure up to that moment. Similarly, for pregnant
women on antiretroviral therapy before conception, HIV
exposure was computed as the viral load assessed at the time
of the first prenatal care appointment. It was assumed that the
observed viral load had been constant during previous
periods. For those women who began to receive antiretroviral
therapy during pregnancy, presenting an undetectable viral
load at the first prenatal visit and lacking a baseline viral load
determination, HIV exposure for previous periods was listed
as missing data. However, whenever HIV viral load was > 400
copies/mL at the first prenatal visit, despite the use of
antiretroviral agents, that value was used to compute HIV
exposure for the previous periods. For pregnant women for
whom the antiretroviral regimen was altered during more than
one week after the last perinatal viral load assessment, HIV
exposure for that period was listed as missing data.
For each gestation period, HIV exposure was categorized
as < 1,000 copies/mL or ≥ 1,000 copies/mL. The viral loads of
the mothers who transmitted HIV were analyzed in comparison
to the viral loads of non-transmitters in each of the above-
mentioned gestation periods in order to assess the potential
relevance of viremia for transmission in relation to the
gestation period. This study was approved by the UNIFESP
Ethics Committee and was in compliance with applicable
Brazilian and international ethical standards.
Descriptive analyses were used to characterize the
population. Correlations between HIV viral loads and MTCT
were determined using Fisher’s exact test. All analyses were
performed with SPSS for Windows, version 10.0 (SPSS, Inc.,
Chicago, IL, USA). Values of P < 0.05 were considered
statistically significant.
Results
From January 1999 to June 2004, 457 HIV-positive pregnant
women were treated. Of those 457, 53 were excluded from the
final analyses: 31 because they dropped out of prenatal care;
seven due to abortion/miscarriage; eight because of fetal
death; and seven because their patient records lacked data
regarding HIV viral load or antiretroviral therapy, although no
HIV transmission occurred in these latter seven cases.
Therefore, the final sample consisted of 404 women, 141 (34.9%)
of whom became aware of their HIV status during the current
pregnancy, and 263 (65.1%) of whom were not on antiretroviral
therapy when they conceived. The mean age was 28 years
(range, 14-46 years), and median gestational age at the first
prenatal care visit was 20 weeks (range, 6.5-38 weeks). Prenatal
care began at 28 weeks of gestation or later in 122 (30.2%) of
the women, and after 35 weeks in 11 (2%).
Initial median CD4+ T-cell counts and HIV viral load in
pregnancy were 372 cells/mm3 (range, 2−1,423 cells/mm3) and
8,400 copies/mL (range, < 80−1,900,000 copies/mL),
respectively. Highly active antiretroviral therapy (HAART)
during pregnancy was used by 378 (93.6%) of the women:
nevirapine by 191 (47.4%), and protease inhibitor by 187
(46.2%). Exclusive zidovudine monotherapy and double-
nucleoside analog therapy were prescribed to, respectively,
seven (1.7%) and 16 (4%) of the women. The remaining three
pregnant women (0.7%) received zidovudine monotherapy at
delivery. Of the 391 cases for which perinatal laboratory test
results were available, HIV viral load was below the level of
detection in 282 (72.1%).
Elective C-section was performed in 277 (68.5%) of the 404
cases investigated, urgent C-section in 73 (18.1%), and vaginal
delivery in 54 (13.4%). Premature delivery occurred in 58
(14.4%) of the cases.
Among the 404 women evaluated, the rate of MTCT was
only 0.49% (2/404; 95% confidence interval (CI): 0.14−1.79%).
The first case of transmission occurred in 1999 in a woman
who had started antiretroviral therapy long before becoming
pregnant. At the time of conception, the woman was on
zidovudine and lamivudine. At the first prenatal visit (at week
22 of gestation), her HIV viral load was determined to be 25,000
copies/mL, and a CD4+ count of 120 cells/mm3 was recorded.
Consequently, HAART (nelfinavir, stavudine and didanosine)
was initiated. Her HIV viral load was maintained at
approximately 25,000 copies/mL throughout gestation and the
elective C-section was done at 38 weeks. No data regarding
genotyping or adherence were available. Since the offspring
HIV-1 Viremia and Pregnancy
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viral load was only measured one month after birth, it was not
possible to determine whether transmission was intrauterine
or not. The second case occurred in 2002 in a woman who was
on zidovudine, lamivudine and indinavir before conception.
She began prenatal care at 23 weeks of gestation, at which
time her HIV viral load was 3,400 copies/mL, and her CD4+
count was 376 cells/mm3. Despite several attempts to
determine the genotype, amplification was unsuccessful. At
31 weeks of gestation, the patient was put on lopinavir/r,
didanosine and stavudine. Her HIV viral load remained > 1,000
copies/mL throughout gestation and was 1,510 copies/mL at
the time of C-section (at 38 weeks). In this case, HIV intrauterine
transmission was confirmed. The relevance of HIV viral load
to HIV transmission for the two infected offspring was
analyzed for each of the pregnancy periods: < 14 weeks, from
14-28 weeks, and > 28 weeks.
Median HIV viral load during the 0 to 14 weeks of gestation
period was 9,900 copies/mL (interquartile range, 1000−50,775
copies/mL). The MTCT rate among women with HIV viral
loads ≥ 1,000 copies/mL during this period was 0.67% (2/298;
95% CI: 0.18−2.41), compared with 0% among those with HIV
viral loads < 1,000 copies/mL (P = 1). In the 14 to 28 week
period, the median HIV viral load to which fetuses were
exposed was 8,350 copies/mL (interquartile range, 707−42,000
copies/mL). For this period, there was also no significant
difference in MTCT rates between women with HIV viral loads
≥ 1,000 copies/mL (0.68%; 2/292; 95% CI: 0.19−2.45%) and the
remaining women (0%; P = 1). At 28 weeks or more of gestation,
the median HIV viral load to which fetuses were exposed was
435 copies/mL (interquartile range, 90−7775 copies/mL),
During this period, the MTCT rate among those with HIV
viral loads = 1,000 copies/mL was 1.15% (2/173; 95% CI: 0.32−
4.12) and 0% among those with < 1,000 copies/mL (P = 0.18).
The median HIV viral load to which fetuses were exposed in
the perinatal period was below the lower limit of detection of
400 copies/mL (interquartile range, 80−500 copies/mL). The
perinatal MTCT rate was 2.81% (2/71; 95% CI: 0.34−9.8) among
women with ≥ 1,000 copies/mL and 0% among those with <
1000 copies/mL (P = 0.032).
For the 0 to 14 weeks of gestation period, HIV viral load
data were missing for 10 women, who were therefore
unaccounted for in the analysis of this period. There was a
similar lack of data for six women in relation to the 14 to 28
week period. For the perinatal period, HIV viral load data were
not collected for 13 patients.
Discussion
We found that exposure to viral loads > 1,000 copies/mL
in the first 28 weeks of gestation is not associated with
increased risk of MTCT of HIV. Neither the probability of
achieving a perinatal HIV viral load < 1,000 copies/mL nor the
risk of MTCT were affected by postponing HAART initiation
to after 28 weeks of gestation.
The rate of MTCT in our study was 0.49% (2/404), whereas
the rate in Brazil as a whole, during 2000 to 2002, was 6.8%,
ranging from 12.3% in the northeastern region to 5.5% in the
south [19]. Such a striking difference could be attributed to
the multidisciplinary approach of the facilities participating in
our study, as well as to the use of HAART, as opposed to
zidovudine monotherapy, the latter still being recommended
in the Brazilian guidelines for antiretroviral therapy
administered to pregnant women [14]. In the Netherlands,
exclusive use of HAART after 21 weeks of gestation resulted
in a similar MTCT rate (0.7%; 2/267) [20].
The relevance of mean prenatal viral load for MTCT was
stressed by Magder et al. [12] in the Women and Infants
Transmission Study cohort. However, averaging viral loads
determined throughout pregnancy precludes any conclusion
about the contribution of viral load exposure in each gestation
period, i.e. first versus third trimester. In our study, HIV viral
loads during the first 14 weeks of gestation were < 1,000 copies/
mL in only 24.4% (96/394) of the women evaluated, > 100,000
copies/mL in 14% (55/394) and above the upper detection
limit of 750,000 copies/mL in 1% (4/394). For the same period,
the MTCT rate among women with viral loads > 1,000 copies/
mL was not significantly higher than that seen among women
with viral loads = 1,000 copies/mL. During this period, there
were six miscarriages among women; they had a median viral
load of 5,350 copies/mL, ranging from undetectable to 390,000
copies/mL. Even assuming that all miscarriages were due to
HIV infection, this could not be explained on the grounds of
viral load alone.
In the 14 to 28 week period, there was also no significant
difference between the rate of MTCT among women presenting
HIV viral loads ≥ 1,000 copies/mL and that among those with
viral loads < 1,000 copies/mL. During this period, viral loads
were > 1,000 copies/mL in 294 women (73.9%) and > 100,000
copies/mL in 52 (13%).
The two women who transmitted HIV to their offspring
had viral loads in the first 28 weeks of only 3,500 and 25,000
copies/mL, respectively, and both had peripartum viral loads
of 1,000 to 24,000 copies/mL. These women were already on
HAART at the time of conception and HAART was continued
throughout pregnancy.
These data support the concept that the introduction of
antiretroviral prophylaxis during the first 28 weeks of gestation
does not have an impact on MTCT. Nevertheless, guidelines
for the prevention of MTCT recommend that antiretroviral
therapy be initiated after 14 weeks of gestation [14,15]. The
timing of antiretroviral therapy initiation was established in
1994, on the basis of the Pediatric AIDS Clinical Trial Group
(PACTG) 076 study [21]. However, closer examination of the
PACTG 076 data reveals no evidence to support the
conclusion that antiretroviral therapy initiated at 14 weeks of
gestation is more effective than that initiated at 26 weeks. In
the PACTG 076 protocol, prior to randomization, pregnant
women were stratified according to gestational age at study
HIV-1 Viremia and Pregnancy
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entry (14 to 26 weeks or 26 to 34 weeks). One conclusion of
the PACTG 076 study was that MTCT rates did not differ
between women in whom zidovudine had been started before
week 26 of gestation and those in whom it had been started
later. In the multivariate analysis, including timing of
antiretroviral therapy initiation, the only variable that
correlated significantly with MTCT was the use of zidovudine.
In fact, intrauterine transmission in the PACTG 076 study was
2% [16], similar to the 1.6% found by Lallement et al. [13], who
used zidovudine alone starting at 28 weeks of gestation.
Therefore, intrauterine transmission does not seem to be
reduced by initiating antiretroviral therapy early in pregnancy.
It is notable that use of antiretroviral therapy as prophylaxis
against MTCT for longer periods can increase both non-
adherence to the regimen and health care system expenditures.
In addition, the extent of genotoxicity, as a result of long-term
fetal exposure to antiretroviral therapy and the consequent
incorporation of nucleoside analogs into the offspring DNA
[22], is still unknown.
In contrast, perinatal viral load > 1,000 copies/mL was
found to be a clear risk factor for MTCT (P = 0.03). Viral load at
delivery has also been shown to be highly predictive of MTCT
in a variety of settings [11,23,24], Shapiro et al. [25]
demonstrated that HAART significantly reduced MTCT
among pregnant women; the percentage women with viral
loads < 1,000 copies/mL was significantly lower among those
on HAART than among those on zidovudine monotherapy.
In conclusion, we suggest that intrauterine transmission
is not influenced by HIV viremia during the first 28 weeks of
gestation. We can therefore argue that the current
recommendation to initiate antiretroviral prophylaxis at 14
weeks of gestation may indeed be doing fetuses more harm
than good.
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